MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT04559555 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia (ALL)

Interventions

DRUG: Nilotinib

Sponsor

Novartis Pharmaceuticals